| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7825246 | IMPACT | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(2 years from now) | |
| US7528143 | IMPACT | Bi-aryl meta-pyrimidine inhibitors of kinases |
Nov, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8138199 | IMPACT | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
Jun, 2028
(4 years from now) | |
| US10391094 | IMPACT | Compositions and methods for treating myelofibrosis |
Jun, 2032
(8 years from now) | |
| US11400092 | IMPACT | Methods of treating myeloproliferative disorders |
Sep, 2039
(15 years from now) | |
Inrebic is owned by Impact.
Inrebic contains Fedratinib Hydrochloride.
Inrebic has a total of 5 drug patents out of which 0 drug patents have expired.
Inrebic was authorised for market use on 16 August, 2019.
Inrebic is available in capsule;oral dosage forms.
Inrebic can be used as treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent, treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.
Drug patent challenges can be filed against Inrebic from 17 August, 2023.
The generics of Inrebic are possible to be released after 24 September, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring...
Dosage: CAPSULE;ORAL
INREBIC family patents
